Proqr Therapeutics (PRQR)

$1.84 -0.15 (-7.54%)
Market Cap 209.67M
Revenue (ttm) 18.00M
Net Income (ttm) -47.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -265.17%
Debt to Equity Ratio 0.10
Volume 925,100
Avg Vol 449,298
Day's Range N/A - N/A
Shares Out 105.36M
Stochastic %K 34%
Beta 0.10
Analysts Strong Sell
Price Target $8.88

Company Profile

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 88 166 7000
Address:
Zernikedreef 9, Leiden, Netherlands
dirkfrank
dirkfrank Apr. 20 at 9:10 PM
$PRQR
1 · Reply
justfacts1
justfacts1 Apr. 20 at 6:55 PM
$PRQR what just happened?
0 · Reply
SBL71
SBL71 Apr. 16 at 7:58 PM
$PRQR according to Schwab platform I need to contact a broker to place a buy order...
3 · Reply
Brandonswest
Brandonswest Apr. 16 at 3:25 PM
$CADL lol, did all that postong thinking i was on the $PRQR page. I suck. $CADL is rad tho.
1 · Reply
struminbanjobio
struminbanjobio Apr. 15 at 10:40 PM
$PRQR https://www.mckinsey.com/capabilities/growth-marketing-and-sales/our-insights/inspired-for-business-growth-how-five-companies-beat-the-market Good adoption move for PRQR
0 · Reply
struminbanjobio
struminbanjobio Apr. 14 at 11:15 PM
$PRQR Bio-AI-mania has begun
1 · Reply
LeftyT
LeftyT Apr. 14 at 11:03 PM
$PRQR I doubled my position in the 1.50-1.61 range last week, and I'm starting to get that "do you feel me now?" kinda vibe. This is still so cheap compared to it's future potential that I have to believe it will continue to run up going into their P1 data PR... coming to a theator near you... soon. GLTA longs!
1 · Reply
george4it
george4it Apr. 14 at 10:00 PM
$PRQR I bought in heavy today.
1 · Reply
Lightbeeronice
Lightbeeronice Apr. 14 at 9:46 PM
$PRQR Nice.
0 · Reply
FutureInvesting777
FutureInvesting777 Apr. 13 at 12:44 PM
$PRQR They have got to show a glimpse of the “pro claimed” holy grail; that’s data. Until then, it continues to be “open season” :).
0 · Reply
Latest News on PRQR
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

Apr 8, 2026, 4:00 PM EDT - 12 days ago

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

Apr 8, 2026, 8:00 AM EDT - 12 days ago

ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

Mar 25, 2026, 8:00 AM EDT - 26 days ago

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

ProQR Announces Year End 2025 Operating and Financial Results

Mar 12, 2026, 7:00 AM EDT - 5 weeks ago

ProQR Announces Year End 2025 Operating and Financial Results

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

Mar 3, 2026, 4:30 PM EST - 6 weeks ago

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

ProQR Announces Planned Changes to Board Composition

Feb 9, 2026, 8:00 AM EST - 2 months ago

ProQR Announces Planned Changes to Board Composition

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Jan 8, 2026, 8:00 AM EST - 3 months ago

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Dec 1, 2025, 8:00 AM EST - 5 months ago

ProQR to Participate in 8th Annual Evercore Healthcare Conference

ProQR Announces Third Quarter 2025 Operating and Financial Results

Nov 6, 2025, 7:00 AM EST - 5 months ago

ProQR Announces Third Quarter 2025 Operating and Financial Results

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

Oct 20, 2025, 8:00 AM EDT - 6 months ago

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

ProQR to Participate in Upcoming Investor Conferences in October 2025

Oct 13, 2025, 8:30 AM EDT - 6 months ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

ProQR Announces Second Quarter 2025 Operating and Financial Results

Aug 7, 2025, 7:00 AM EDT - 9 months ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

ProQR Announces Upcoming Presentation at RNA Editing Summit

Jul 28, 2025, 8:00 AM EDT - 9 months ago

ProQR Announces Upcoming Presentation at RNA Editing Summit

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

Jun 26, 2025, 4:30 PM EDT - 10 months ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 12, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

ProQR Announces First Quarter 2025 Operating and Financial Results

May 8, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2025 Operating and Financial Results

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 2, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Apr 14, 2025, 7:00 AM EDT - 1 year ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

ProQR Announces Year End 2024 Operating and Financial Results

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2024 Operating and Financial Results

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Dec 10, 2024, 8:00 AM EST - 1 year ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 25, 2024, 4:45 PM EDT - 1 year ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 1 year ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 22, 2024, 4:01 PM EDT - 1 year ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 4:30 PM EDT - 1 year ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

ProQR Announces First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces First Quarter 2024 Operating and Financial Results

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 23, 2024, 7:00 AM EDT - 2 years ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 22, 2024, 4:31 PM EDT - 2 years ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Apr 19, 2024, 7:00 AM EDT - 2 years ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

ProQR Announces Year End 2023 Operating and Financial Results

Mar 13, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces Year End 2023 Operating and Financial Results

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 19, 2024, 7:00 AM EST - 2 years ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Jan 5, 2024, 7:00 AM EST - 2 years ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Dec 8, 2023, 7:30 AM EST - 2 years ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 7, 2023, 7:00 AM EST - 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Nov 6, 2023, 7:00 AM EST - 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 28, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 3, 2023, 7:00 AM EDT - 2 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Aug 1, 2023, 7:00 AM EDT - 2 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

Jul 6, 2023, 7:00 AM EDT - 3 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

May 9, 2023, 8:00 AM EDT - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

ProQR Announces Upcoming Investor Conferences in April and May

Apr 20, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Upcoming Investor Conferences in April and May

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Apr 18, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Mar 29, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Mar 14, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

ProQR to Present at Upcoming Scientific and Industry Conferences

Mar 7, 2023, 8:00 AM EST - 3 years ago

ProQR to Present at Upcoming Scientific and Industry Conferences

ProQR's stock jumps on expanded RNA deal with Lilly

Dec 22, 2022, 9:12 AM EST - 3 years ago

ProQR's stock jumps on expanded RNA deal with Lilly

LLY

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Dec 22, 2022, 6:15 AM EST - 3 years ago

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Lilly and ProQR to Expand RNA Editing Collaboration

Dec 22, 2022, 6:00 AM EST - 3 years ago

Lilly and ProQR to Expand RNA Editing Collaboration

LLY

dirkfrank
dirkfrank Apr. 20 at 9:10 PM
$PRQR
1 · Reply
justfacts1
justfacts1 Apr. 20 at 6:55 PM
$PRQR what just happened?
0 · Reply
SBL71
SBL71 Apr. 16 at 7:58 PM
$PRQR according to Schwab platform I need to contact a broker to place a buy order...
3 · Reply
Brandonswest
Brandonswest Apr. 16 at 3:25 PM
$CADL lol, did all that postong thinking i was on the $PRQR page. I suck. $CADL is rad tho.
1 · Reply
struminbanjobio
struminbanjobio Apr. 15 at 10:40 PM
$PRQR https://www.mckinsey.com/capabilities/growth-marketing-and-sales/our-insights/inspired-for-business-growth-how-five-companies-beat-the-market Good adoption move for PRQR
0 · Reply
struminbanjobio
struminbanjobio Apr. 14 at 11:15 PM
$PRQR Bio-AI-mania has begun
1 · Reply
LeftyT
LeftyT Apr. 14 at 11:03 PM
$PRQR I doubled my position in the 1.50-1.61 range last week, and I'm starting to get that "do you feel me now?" kinda vibe. This is still so cheap compared to it's future potential that I have to believe it will continue to run up going into their P1 data PR... coming to a theator near you... soon. GLTA longs!
1 · Reply
george4it
george4it Apr. 14 at 10:00 PM
$PRQR I bought in heavy today.
1 · Reply
Lightbeeronice
Lightbeeronice Apr. 14 at 9:46 PM
$PRQR Nice.
0 · Reply
FutureInvesting777
FutureInvesting777 Apr. 13 at 12:44 PM
$PRQR They have got to show a glimpse of the “pro claimed” holy grail; that’s data. Until then, it continues to be “open season” :).
0 · Reply
RandomInvestor777
RandomInvestor777 Apr. 11 at 5:59 PM
$PRQR lmao AI...fucking joke. the entire mgmt team should be fired
1 · Reply
dirkfrank
dirkfrank Apr. 11 at 4:24 PM
$PRQR im westen nichts neues
0 · Reply
Bobfree
Bobfree Apr. 10 at 2:04 PM
$PRQR For their next target if they were to consider iron regulation via TMPRSS6 they could tackle the anemia which apparently most of investors suffer from.
0 · Reply
red75
red75 Apr. 10 at 1:09 AM
$PRQR
0 · Reply
johnnygogogo
johnnygogogo Apr. 9 at 10:05 PM
$PRQR never forget that Charles Schwab blocked investors from buying this
1 · Reply
Rodom3001
Rodom3001 Apr. 9 at 3:37 PM
$PRQR can we do something already; anything… lol
0 · Reply
johnnygogogo
johnnygogogo Apr. 9 at 2:50 PM
$PRQR right now, the sub $2 market maker is negotiating a handoff of the baton to the $2+ market maker / underwriters getting into position on potential positive data readout later this q. Trading chop shops that “provide liquidity” like Susquehanna can F off. Also nice to see Morgan Scamley sold half their position last q. And without naming names, happy to see certain “influencers” on the sidelines right now. @skeezbag
0 · Reply
KostasBars
KostasBars Apr. 9 at 1:41 PM
$PRQR get ready. I said this 2 days ago. It’s forced past €2.02. , let’s see
0 · Reply
Filvul
Filvul Apr. 9 at 9:48 AM
$PRQR
0 · Reply
focafoca99
focafoca99 Apr. 8 at 10:17 PM
$PRQR used its investor event to highlight pipeline expansion, AX-0810 data expected this quarter, and additional programs moving toward the clinic.
0 · Reply
buymoremakemore
buymoremakemore Apr. 8 at 9:52 PM
$PRQR if data is good here in June, I dont see how this doesnt stabilize to at least $2.5. Maybe $3 after target patient data in Q4.
2 · Reply
Smarting1121
Smarting1121 Apr. 8 at 9:37 PM
$PRQR I like that price & volume picked up considerably in afternoon trading. I guess the market needed some time to digest this news. Hoping for continued positive price movement heading into June data readout.
0 · Reply